We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.33B
AUM Growth
+$549M
Cap. Flow
-$84M
Cap. Flow %
-3.6%
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65

Top Buys

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$59M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.1M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.18M
4
AGN
Allergan plc
AGN
+$6.91M
5
PSTV icon
Plus Therapeutics
PSTV
+$6.73M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$8.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.12M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.64M

Sector Composition

Rank Sector Weight
1 Healthcare 9.43%
2 Real Estate 2.82%
3 Energy 0.36%
4 Consumer Discretionary 0.23%
5 Communication Services 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VNDA icon
101
Vanda Pharmaceuticals
VNDA
$310M
$2.1M 0.09%
+130,000
New +$1.73M
FURX
102
CALL
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$2.05M 0.09%
193
+41
+27% +$4.02K
OPK icon
103
CALL
Opko Health
OPK
$1.23B
$2.04M 0.09%
22,661
+2,559
+13% +$22.3K
GWPH
104
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.02M 0.09%
+188
New +$13.1K
NBIX icon
105
CALL
Neurocrine Biosciences
NBIX
$18.4B
$1.97M 0.08%
1,327
+20
+2% +$282
TVTX icon
106
CALL
Travere Therapeutics
TVTX
$5.2B
$1.96M 0.08%
+1,670
New +$22.6K
NVO
107
PUT
Novo Nordisk
NVO
$225B
$1.96M 0.08%
+848
New +$18.7K
NVAX icon
108
Novavax
NVAX
$1.21B
$1.93M 0.08%
20,919
+8,344
+66% +$733K
CARM
109
DELISTED
Carisma Therapeutics
CARM
$1.9M 0.08%
+7,199
New +$1.78M
ACGN
110
DELISTED
Aceragen Inc
ACGN
$1.79M 0.08%
4,538
+4,428
+4,025% +$1.83M
MRK icon
111
PUT
Merck
MRK
$326B
$1.74M 0.07%
314
-7,016
-96% -$383K
LITS
112
Lite Strategy Inc
LITS
$33M
$1.71M 0.07%
+13,500
New +$1.98M
SLXP
113
CALL
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$1.69M 0.07%
+137
New +$15.1K
HRTX icon
114
Heron Therapeutics
HRTX
$92M
$1.67M 0.07%
+135,281
New +$1.62M
TPST icon
115
Tempest Therapeutics
TPST
$13.9M
$1.66M 0.07%
62
-60
-49% -$1.41M
XNTK icon
116
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
$1.63M 0.07%
212
-3,800
-95% -$175K
ICPT
117
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.61M 0.07%
+68
New +$17.9K
CEMP
118
DELISTED
Cempra, Inc.
CEMP
$1.6M 0.07%
149,000
-256,946
-63% -$2.48M
PGNX
119
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$1.57M 0.07%
365,186
-152,608
-29% -$583K
TSRO
120
PUT
DELISTED
TESARO, Inc.
TSRO
$1.56M 0.07%
+500
New +$13.3K
ANTH
121
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.52M 0.07%
56,000
-30,005
-35% -$741K
EPZM
122
DELISTED
Epizyme, Inc
EPZM
$1.52M 0.07%
48,790
-102,430
-68% -$2.41M
SCTL
123
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$1.5M 0.06%
208,438
-45,551
-18% -$277K
AMPE
124
PUT
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$1.5M 0.06%
6
– –
BMY icon
125
Bristol-Myers Squibb
BMY
$130B
$1.45M 0.06%
+29,949
New +$1.48M
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sabby Management withdrew a net $84M in Q2 2014, closing 65 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, down from 10% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Sabby Management opened a new position in Weyerhaeuser worth $64.6M.

  • Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
  • Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
  • Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
  • Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
  • Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
  • Sabby Management opened 83 new positions and closed 65 in Q2 2014.
  • Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.